Summary of Adverse Events
Weeks 0 to 12
All Participants as Treated

| | Placebo | | Xanomeline Low Dose | | Xanomeline High Dose | | Total | |
|---|---|---|---|---|---|---|---|---|
| | n | (%) | n | (%) | n | (%) | n | (%) |
| Participants in population | xx | | xx | | xx | | xxx | |
| with one or more adverse events | xx | (xx.x) | xx | (xx.x) | xx | (xx.x) | xxx | (xx.x) |
| with drug-related[a] adverse events | xx | (xx.x) | xx | (xx.x) | xx | (xx.x) | xxx | (xx.x) |
| with serious adverse events | x | (x.x) | x | (x.x) | x | (x.x) | x | (x.x) |

[a]Determined by the investigator to be related to the drug.

Source: [CDISCpilot: adam-adsl; adae]